A citation-based method for searching scientific literature

Liping Chu, Yuxiu Qu, Yang An, Linjun Hou, Juewan Li, Weijia Li, Gaofeng Fan, Bao-Liang Song, En Li, Liye Zhang, Wei Qi. Cell Death Dis 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Epigenetic Therapies for Cancer.
Susan E Bates. N Engl J Med 2020
122
100

Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia.
N Cerveira, C Correia, S Dória, S Bizarro, P Rocha, P Gomes, L Torres, L Norton, B S Borges, S Castedo,[...]. Leukemia 2003
48
100

A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
David Dilworth, Ronan P Hanley, Renato Ferreira de Freitas, Abdellah Allali-Hassani, Mengqi Zhou, Naimee Mehta, Matthew R Marunde, Suzanne Ackloo, Raquel Arminda Carvalho Machado, Aliakbar Khalili Yazdi,[...]. Nat Chem Biol 2022
7
100

The Role of Lysine Methyltransferase SET7/9 in Proliferation and Cell Stress Response.
Alexandra Daks, Elena Vasileva, Olga Fedorova, Oleg Shuvalov, Nickolai A Barlev. Life (Basel) 2022
2
100

A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome.
Keisuke Nimura, Kiyoe Ura, Hidetaka Shiratori, Masato Ikawa, Masaru Okabe, Robert J Schwartz, Yasufumi Kaneda. Nature 2009
269
100

NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).
Roberto Rosati, Roberta La Starza, Angelo Veronese, Ana Aventin, Christine Schwienbacher, Teresa Vallespi, Massimo Negrini, Massimo F Martelli, Cristina Mecucci. Blood 2002
132
100

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
S Struski, S Lagarde, P Bories, C Puiseux, N Prade, W Cuccuini, M-P Pages, A Bidet, C Gervais, M Lafage-Pochitaloff,[...]. Leukemia 2017
52
100

Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase.
H Wang, R Cao, L Xia, H Erdjument-Bromage, C Borchers, P Tempst, Y Zhang. Mol Cell 2001
406
100

EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Ananya Pal, Jia Yu Leung, Gareth Chin Khye Ang, Vinay Kumar Rao, Luca Pignata, Huey Jin Lim, Maxime Hebrard, Kenneth Te Chang, Victor Km Lee, Ernesto Guccione,[...]. Elife 2020
5
100

Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Irfan A Asangani, Bushra Ateeq, Qi Cao, Lois Dodson, Mithil Pandhi, Lakshmi P Kunju, Rohit Mehra, Robert J Lonigro, Javed Siddiqui, Nallasivam Palanisamy,[...]. Mol Cell 2013
99
100

Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Shilin Xu, Angelo Aguilar, Tianfeng Xu, Ke Zheng, Liyue Huang, Jeanne Stuckey, Krishnapriya Chinnaswamy, Denzil Bernard, Ester Fernández-Salas, Liu Liu,[...]. Angew Chem Int Ed Engl 2018
37
100

DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rachel E Rau, Benjamin A Rodriguez, Min Luo, Mira Jeong, Allison Rosen, Jason H Rogers, Carly T Campbell, Scott R Daigle, Lishing Deng, Yongcheng Song,[...]. Blood 2016
75
100

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
William N Pappano, Jun Guo, Yupeng He, Debra Ferguson, Sujatha Jagadeeswaran, Donald J Osterling, Wenqing Gao, Julie K Spence, Marina Pliushchev, Ramzi F Sweis,[...]. PLoS One 2015
48
100

Target validation using chemical probes.
Mark E Bunnage, Eugene L Piatnitski Chekler, Lyn H Jones. Nat Chem Biol 2013
258
100

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
Angelo Aguilar, Ke Zheng, Tianfeng Xu, Shilin Xu, Liyue Huang, Ester Fernandez-Salas, Liu Liu, Denzil Bernard, Kaitlin P Harvey, Caroline Foster,[...]. J Med Chem 2019
14
100

A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region.
T J Wright, D O Ricke, K Denison, S Abmayr, P D Cotter, K Hirschhorn, M Keinänen, D McDonald-McGinn, M Somer, N Spinner,[...]. Hum Mol Genet 1997
180
100

Chemogenetic analysis of human protein methyltransferases.
Victoria M Richon, Danielle Johnston, Christopher J Sneeringer, Lei Jin, Christina R Majer, Keith Elliston, L Fred Jerva, Margaret Porter Scott, Robert A Copeland. Chem Biol Drug Des 2011
139
100

Protein arginine methylation: from enigmatic functions to therapeutic targeting.
Qin Wu, Matthieu Schapira, Cheryl H Arrowsmith, Dalia Barsyte-Lovejoy. Nat Rev Drug Discov 2021
38
100

PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
Jingfeng Zhou, Danian Nie, Juan Li, Xin Du, Yuhong Lu, Yangqiu Li, Chang Liu, Wei Dai, Yun Wang, Yanli Jin,[...]. Clin Cancer Res 2018
20
100

Roles and regulation of histone methylation in animal development.
Ashwini Jambhekar, Abhinav Dhall, Yang Shi. Nat Rev Mol Cell Biol 2019
155
100

Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype.
Paolo Zanoni, Katharina Steindl, Deepanwita Sengupta, Pascal Joset, Angela Bahr, Heinrich Sticht, Mariarosaria Lang-Muritano, Conny M A van Ravenswaaij-Arts, Marwan Shinawi, Marisa Andrews,[...]. Genet Med 2021
5
100

Epigenetic regulation of development by histone lysine methylation.
S Dambacher, M Hahn, G Schotta. Heredity (Edinb) 2010
65
100

Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Hao Lei, San-Qi Zhang, Shu Fan, Huan-Rong Bai, Hong-Yi Zhao, Shuai Mao, Minhang Xin. J Med Chem 2021
2
100

EZH2 Y641 mutations in follicular lymphoma.
C Bödör, C O'Riain, D Wrench, J Matthews, S Iyengar, H Tayyib, M Calaminici, A Clear, S Iqbal, H Quentmeier,[...]. Leukemia 2011
91
100

Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.
J A Oyer, X Huang, Y Zheng, J Shim, T Ezponda, Z Carpenter, M Allegretta, C I Okot-Kotber, J P Patel, A Melnick,[...]. Leukemia 2014
87
100

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.
Jacson K Shen, Gregory M Cote, Yan Gao, Edwin Choy, Henry J Mankin, Francis J Hornicek, Zhenfeng Duan. Sci Rep 2016
38
100

p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice.
Bernhard Lehnertz, Jason C Rogalski, Felix M Schulze, Lin Yi, Shujun Lin, Jürgen Kast, Fabio M V Rossi. Mol Cell 2011
63
100

(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.
Dalia Barsyte-Lovejoy, Fengling Li, Menno J Oudhoff, John H Tatlock, Aiping Dong, Hong Zeng, Hong Wu, Spencer A Freeman, Matthieu Schapira, Guillermo A Senisterra,[...]. Proc Natl Acad Sci U S A 2014
115
100

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Sarah K Knutson, Tim J Wigle, Natalie M Warholic, Christopher J Sneeringer, Christina J Allain, Christine R Klaus, Joelle D Sacks, Alejandra Raimondi, Christina R Majer, Jeffrey Song,[...]. Nat Chem Biol 2012
565
100

NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
Christopher A French, Shaila Rahman, Erica M Walsh, Simone Kühnle, Adlai R Grayson, Madeleine E Lemieux, Noam Grunfeld, Brian P Rubin, Cristina R Antonescu, Songlin Zhang,[...]. Cancer Discov 2014
135
100

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, Jemma Longley, Juanita Lopez, Jean-Marie Michot, John P Leonard, Vincent Ribrag, Michael T McCabe, Caretha L Creasy,[...]. Clin Cancer Res 2019
63
100

Tazemetostat: First Approval.
Sheridan M Hoy. Drugs 2020
90
100

Targeting histone lysine methylation in cancer.
John McGrath, Patrick Trojer. Pharmacol Ther 2015
136
100

SET domains and histone methylation.
Bing Xiao, Jonathan R Wilson, Steven J Gamblin. Curr Opin Struct Biol 2003
121
100


Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells.
Gabriela Vilema-Enríquez, Robert Quinlan, Peter Kilfeather, Roberta Mazzone, Saba Saqlain, Irene Del Molino Del Barrio, Annalidia Donato, Gabriele Corda, Fengling Li, Masoud Vedadi,[...]. J Biol Chem 2020
5
100

Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Xuejiao Song, Tiantao Gao, Ningyu Wang, Qiang Feng, Xinyu You, Tinghong Ye, Qian Lei, Yongxia Zhu, Menghua Xiong, Yong Xia,[...]. Sci Rep 2016
37
100

The Polycomb complex PRC2 and its mark in life.
Raphaël Margueron, Danny Reinberg. Nature 2011
100

Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.
Wenyu Yu, David Smil, Fengling Li, Wolfram Tempel, Oleg Fedorov, Kong T Nguyen, Yuri Bolshan, Rima Al-Awar, Stefan Knapp, Cheryl H Arrowsmith,[...]. Bioorg Med Chem 2013
48
100

Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
Jark Böttcher, David Dilworth, Ulrich Reiser, Ralph A Neumüller, Michael Schleicher, Mark Petronczki, Markus Zeeb, Nikolai Mischerikow, Abdellah Allali-Hassani, Magdalena M Szewczyk,[...]. Nat Chem Biol 2019
27
100

Regulation of chromatin structure by site-specific histone H3 methyltransferases.
S Rea, F Eisenhaber, D O'Carroll, B D Strahl, Z W Sun, M Schmid, S Opravil, K Mechtler, C P Ponting, C D Allis,[...]. Nature 2000
100

The diverse functions of histone lysine methylation.
Cyrus Martin, Yi Zhang. Nat Rev Mol Cell Biol 2005
100

The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.
Tianfu Yu, Yingyi Wang, Qi Hu, WeiNing Wu, Youzhi Wu, Wenjin Wei, Dongfeng Han, Yongping You, Ning Lin, Ning Liu. Oncotarget 2017
37
100

The polycomb group protein EZH2 is involved in progression of prostate cancer.
Sooryanarayana Varambally, Saravana M Dhanasekaran, Ming Zhou, Terrence R Barrette, Chandan Kumar-Sinha, Martin G Sanda, Debashis Ghosh, Kenneth J Pienta, Richard G A B Sewalt, Arie P Otte,[...]. Nature 2002
100

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Warren Fiskus, Steffen Boettcher, Naval Daver, Christopher P Mill, Koji Sasaki, Christine E Birdwell, John A Davis, Koichi Takahashi, Tapan M Kadia, Courtney D DiNardo,[...]. Blood Cancer J 2022
2
100

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Jing Tan, Xiaojing Yang, Li Zhuang, Xia Jiang, Wei Chen, Puay Leng Lee, R K Murthy Karuturi, Patrick Boon Ooi Tan, Edison T Liu, Qiang Yu. Genes Dev 2007
687
100


Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
Hualong He, Xi Hu, Fei Teng, Zhihao Liu, Qiangsheng Zhang, Zhanzhan Feng, Qiang Feng, Luoting Yu. Bioorg Med Chem Lett 2020
6
100

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
V Gibaja, F Shen, J Harari, J Korn, D Ruddy, V Saenz-Vash, H Zhai, T Rejtar, C G Paris, Z Yu,[...]. Oncogene 2016
95
100

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Christina R Majer, Christopher J Sneeringer, Jeffrey Song, L Danielle Johnston, Margaret Porter Scott, Jesse J Smith, Yonghong Xiao,[...]. Cancer Cell 2011
654
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.